MCID: ADN021
MIFTS: 71

Adenomatous Polyposis Coli

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases, Bone diseases

Aliases & Classifications for Adenomatous Polyposis Coli

MalaCards integrated aliases for Adenomatous Polyposis Coli:

Name: Adenomatous Polyposis Coli 54 13 69
Gardner Syndrome 54 50 24 56 29 69
Brain Tumor-Polyposis Syndrome 2 54 29 69
Familial Adenomatous Polyposis 56 71
Fap 56 71
Polyposis Coli and Multiple Hard and Soft Tissue Tumors 50
Apc-Related Attenuated Familial Adenomatous Polyposis 56
Intestinal Polyposis, Osteomas, Sebaceous Cysts 50
Apc-Related Attenuated Familial Polyposis Coli 56
Colorectal Adenomatous Polyposis 56
Familial Adenomatous Polyposis 1 29
Turcot Syndrome with Polyposis 56
Apc-Related Attenuated Fap 56
Familial Polyposis Coli 56
Gardner's Syndrome 50
Gardners Syndrome 52
Apc-Related Afap 56

Characteristics:

Orphanet epidemiological data:

56
familial adenomatous polyposis
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-9/100000 (Europe),1-5/10000 (Denmark),1-9/100000 (Denmark),1-9/100000 (Sweden),1-5/10000 (Finland),1-9/100000 (Finland),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/1000000 (Australia),1-9/100000 (Australia); Age of onset: Adult; Age of death: adult;
apc-related attenuated familial adenomatous polyposis
Inheritance: Autosomal dominant,Autosomal recessive;
turcot syndrome with polyposis
Inheritance: Autosomal dominant; Age of onset: All ages;

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
prevalence 1 in 8000
polyps occur in teens
colorectal cancer develops by fourth decade in untreated patients


HPO:

32
adenomatous polyposis coli:
Onset and clinical course variable expressivity
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Adenomatous Polyposis Coli

NIH Rare Diseases : 50 gardner syndromeis a form of familial adenomatous polyposis (fap) that is characterized by multiple colorectal polyps and various types of tumors, both benign (noncancerous) and malignant (cancerous). people affected by gardner syndrome have a high risk of developing colorectal cancer at an early age. they are also at an increased risk of developing other fap-related cancers, such as those of the small bowel, stomach, pancreas, thyroid, central nervous system, liver, bile ducts, and/or adrenal gland. other signs and symptoms of gardner syndrome include dental abnormalities; osteomas (benign bone growths); various skin abnormalities such as epidermoid cysts, fibromas (a benign tumor of the connective tissue), and lipomas; and desmoid tumors. it is caused by changes (mutations) in the apc gene and inherited in an autosomal dominant manner. although there is no cure for gardner syndrome, management options are available to reduce the risk of cancer. these may include high risk screening, prophylactic surgeries and/or certain types of medications. last updated: 1/14/2015

MalaCards based summary : Adenomatous Polyposis Coli, also known as gardner syndrome, is related to hepatocellular carcinoma and colorectal cancer, and has symptoms including colon cancer, multiple gastric polyps and odontoma. An important gene associated with Adenomatous Polyposis Coli is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Signaling by GPCR and HIV Life Cycle. The drugs Erythromycin and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include colon, skin and thyroid, and related phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and cardiovascular system

UniProtKB/Swiss-Prot : 71 Familial adenomatous polyposis: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

OMIM : 54
Familial adenomatous polyposis-1 is an autosomal dominant disorder characterized by predisposition to cancer. Affected individuals usually develop hundreds to thousands of adenomatous polyps of the colon and rectum, a small proportion of which will progress to colorectal carcinoma if not surgically treated. Gardner syndrome is a variant of FAP in which desmoid tumors, osteomas, and other neoplasms occur together with multiple adenomas of the colon and rectum (Nishisho et al., 1991). Rustgi (2007) reviewed the genetics of hereditary colon cancer, including APC. (175100)

Related Diseases for Adenomatous Polyposis Coli

Diseases related to Adenomatous Polyposis Coli via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 27.8 APC AXIN1 CCND1 CDH1 CTNNB1 MYC
2 colorectal cancer 26.2 APC AXIN1 AXIN2 CCND1 CDH1 CTNNB1
3 colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas 12.2
4 familial adenomatous polyposis 11.8
5 samson gardner syndrome 11.8
6 adenomas, multiple colorectal 11.7
7 mutyh-associated polyposis 11.6
8 desmoid tumor 11.5
9 attenuated familial adenomatous polyposis 11.4
10 mismatch repair cancer syndrome 11.2
11 familial adenomatous polyposis due to 5q22.2 microdeletion 11.1
12 anencephaly 10.7 APC CTNNB1
13 desmoplastic small round cell tumor 10.5 APC CTNNB1
14 glycogen storage disease due to lactate dehydrogenase deficiency 10.5 AXIN1 CTNNB1
15 diabetes mellitus, insulin-dependent, 20 10.5 APC CTNNB1
16 adenoma 10.4
17 breast cancer 10.3
18 gorlin bushkell jensen syndrome 10.3 CDH1 CTNNB1
19 squamous cell carcinoma 10.2
20 hepatocellular adenoma 10.2
21 thyroiditis 10.2
22 lung cancer 10.1
23 oral squamous cell carcinoma 10.1
24 colorectal adenoma 10.1
25 neuronitis 10.1
26 breast sarcoma 10.1 CDH1 CTNNB1
27 ameloblastoma 10.0
28 colitis 10.0
29 retinoblastoma 10.0
30 hepatitis 10.0
31 ulcerative colitis 10.0
32 spinal cord dermoid cyst 9.9 AXIN1 AXIN2 CTNNB1
33 gastrointestinal neuroendocrine tumor 9.9 CCND1 CDH1 CTNNB1
34 infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 9.9 CCND1 CDH1
35 duodenitis 9.8
36 colorectal adenocarcinoma 9.8
37 hepatitis c 9.8
38 gastroduodenitis 9.8
39 melanoma 9.8
40 lichen planus 9.8
41 parathyroid carcinoma 9.8
42 basal cell carcinoma 9.8
43 hepatitis c virus 9.8
44 adenocarcinoma 9.8
45 autism spectrum disorder 9.8
46 cerebritis 9.8
47 lymphoma 9.8
48 choriocarcinoma 9.8
49 fibromatosis 9.8
50 cranial nerve palsy 9.8

Graphical network of the top 20 diseases related to Adenomatous Polyposis Coli:



Diseases related to Adenomatous Polyposis Coli

Symptoms & Phenotypes for Adenomatous Polyposis Coli

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Gastroin testinal:
multiple colonic adenomatous polyps
multiple gastric polyps
multiple duodenal polyps
mesenteric fibromatosis

Head And Neck- Teeth:
dental caries
unerupted teeth
supernumerary teeth
odontomas

Chest- Breasts:
mammary fibrosis

Skeletal- Limbs:
endosteal and exosteal osteomas

Neoplasia:
medulloblastoma
astrocytoma
adrenal carcinoma
thyroid papillary carcinoma
periampullary carcinoma
more
Head And Neck- Eyes:
congenital hypertrophy of retinal pigment epithelium (chrpe)

Skeletal- Skull:
skull osteomas, especially involving the mandibular angle

Skin Nails & Hair- Skin:
epidermoid inclusion cysts
fibromas
lipomas
lipofibromas
increased skin pigmentation
more

Clinical features from OMIM:

175100

Human phenotypes related to Adenomatous Polyposis Coli:

56 32 (show all 30)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 colon cancer 56 32 frequent (33%) Frequent (79-30%) HP:0003003
2 multiple gastric polyps 56 32 frequent (33%) Very frequent (99-80%) HP:0004394
3 odontoma 56 32 Occasional (29-5%) HP:0011068
4 multiple lipomas 56 32 Occasional (29-5%) HP:0001012
5 duodenal polyposis 56 32 very rare (1%) Very frequent (99-80%) HP:0004783
6 adenomatous colonic polyposis 56 32 hallmark (90%) Very frequent (99-80%) HP:0005227
7 increased number of teeth 56 32 occasional (7.5%) Occasional (29-5%) HP:0011069
8 medulloblastoma 32 very rare (1%) HP:0002885
9 astrocytoma 32 HP:0009592
10 keloids 32 HP:0010562
11 hepatoblastoma 32 very rare (1%) HP:0002884
12 small intestine carcinoid 32 HP:0006722
13 carious teeth 32 occasional (7.5%) HP:0000670
14 sarcoma 56 Occasional (29-5%)
15 delayed eruption of teeth 56 Occasional (29-5%)
16 adrenocortical carcinoma 32 HP:0006744
17 papillary thyroid carcinoma 32 very rare (1%) HP:0002895
18 irregular hyperpigmentation 56 Occasional (29-5%)
19 neoplasm 56 Frequent (79-30%)
20 fibroma 56 Occasional (29-5%)
21 neoplasm of the central nervous system 56 Occasional (29-5%)
22 adrenocortical adenoma 32 very rare (1%) HP:0008256
23 hyperpigmentation of the skin 32 HP:0000953
24 desmoid tumors 32 very rare (1%) HP:0100245
25 epidermal cyst 32 occasional (7.5%) HP:0200040
26 duodenal adenocarcinoma 32 very rare (1%) HP:0006771
27 fibroadenoma of the breast 32 occasional (7.5%) HP:0010619
28 unerupted tooth 32 occasional (7.5%) HP:0000706
29 osteoma 32 occasional (7.5%) HP:0100246
30 congenital hypertrophy of retinal pigment epithelium 32 occasional (7.5%) HP:0007649

UMLS symptoms related to Adenomatous Polyposis Coli:


abdominal pain, diarrhea

GenomeRNAi Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 8.92 APC AXIN1 AXIN2 GSK3B

MGI Mouse Phenotypes related to Adenomatous Polyposis Coli:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 AMER1 APC AXIN1 AXIN2 CCND1 CDH1
2 cellular MP:0005384 10.15 AMER1 APC APC2 AXIN1 AXIN2 CCND1
3 craniofacial MP:0005382 10.08 AMER1 APC AXIN1 AXIN2 CCND1 CTNNB1
4 growth/size/body region MP:0005378 10.07 GSK3B MYC AMER1 APC APC2 AXIN1
5 digestive/alimentary MP:0005381 10 APC AXIN1 CCND1 CDH1 CTNNB1 GSK3B
6 embryo MP:0005380 9.98 AMER1 APC AXIN1 AXIN2 CDH1 CTNNB1
7 endocrine/exocrine gland MP:0005379 9.95 AXIN2 CCND1 CDH1 CTNNB1 GSK3B MYC
8 limbs/digits/tail MP:0005371 9.8 AMER1 APC AXIN1 AXIN2 CTNNB1 MYC
9 normal MP:0002873 9.76 CCND1 CDH1 CTNNB1 GSK3B MYC APC
10 no phenotypic analysis MP:0003012 9.73 APC AXIN2 CDH1 CTNNB1 GSK3B MYC
11 reproductive system MP:0005389 9.56 APC APC2 AXIN1 AXIN2 CCND1 CDH1
12 skeleton MP:0005390 9.23 AMER1 APC AXIN1 AXIN2 CCND1 CTNNB1

Drugs & Therapeutics for Adenomatous Polyposis Coli

Drugs for Adenomatous Polyposis Coli (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
2
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
3 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
4 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Erythromycin Estolate Phase 4
6 Erythromycin Ethylsuccinate Phase 4
7 Erythromycin stearate Phase 4
8 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
9 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
10 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
13 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
15 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
17
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
18
Sulindac Approved Phase 3,Phase 2 38194-50-2 5352 1548887
19
Loperamide Approved Phase 3 53179-11-6 3955
20
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262 389
21 Cholagogues and Choleretics Phase 2, Phase 3
22 Antidiarrheals Phase 3
23 Antiparasitic Agents Phase 3,Phase 2
24 Antiprotozoal Agents Phase 3,Phase 2
25 Protective Agents Phase 2, Phase 3
26 Cola Nutraceutical Phase 2, Phase 3, Phase 1
27 Omega 3 Fatty Acid Nutraceutical Phase 2, Phase 3
28
Metformin Approved Phase 2 657-24-9 14219 4091
29
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
32
Inulin Approved, Nutraceutical Phase 2 9005-80-5 24763
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
34
Curcumin Investigational Phase 2 458-37-7 969516
35 Hypoglycemic Agents Phase 2
36
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
37 Protein Kinase Inhibitors Phase 2
38 Retinol palmitate Phase 2
39 Turmeric extract Phase 2
40 Antibiotics, Antitubercular Phase 2,Phase 1
41 Antifungal Agents Phase 2,Phase 1
42 Immunosuppressive Agents Phase 2,Phase 1
43 Antioxidants Phase 2
44 retinol Nutraceutical Phase 2
45 Turmeric Nutraceutical Phase 2
46
Bevacizumab Approved, Investigational Phase 1 216974-75-3
47
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
48 Raspberry Approved, Nutraceutical Phase 1
49 Angiogenesis Inhibitors Phase 1
50 Angiogenesis Modulating Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 69)

id Name Status NCT ID Phase Drugs
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
2 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Not yet recruiting NCT02354560 Phase 4 Erythromycin
3 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
4 Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients Terminated NCT00151476 Phase 4 Celecoxib
5 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
6 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
7 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
8 Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps Completed NCT00005094 Phase 3 celecoxib
9 Clinical Approaches to Ileal Pouch Dysfunction Completed NCT00293553 Phase 3
10 Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies Recruiting NCT02263365 Phase 3 Loperamide
11 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Active, not recruiting NCT01483144 Phase 3 Eflornithine plus Sulindac;Eflornithine and Placebo;Sulindac and Placebo
12 Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Terminated NCT00585312 Phase 3 Celecoxib;Placebo
13 Coxib-inhibition of Duodenal Polyp Growth in FAP Terminated NCT00844727 Phase 2, Phase 3 Rofecoxib;placebo
14 A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Withdrawn NCT01245816 Phase 3 Eflornithine plus Sulindac;Eflornithine plus Placebo;Sulindac plus Placebo
15 Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
16 Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Unknown status NCT00319007 Phase 2 Sulindac (drug);VSL#3 (probiotic);Inulin (probiotic)
17 The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study Unknown status NCT01725490 Phase 2 metformin
18 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Completed NCT01187901 Phase 2 Erlotinib;Sulindac;Placebo A;Placebo B
19 Curcumin in Treating Patients With Familial Adenomatous Polyposis Completed NCT00641147 Phase 2 Curcumin
20 Sirolimus and Familial Adenomatous Polyposis (FAP) Recruiting NCT03095703 Phase 2 Sirolimus
21 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Recruiting NCT01265030 Phase 1, Phase 2 Sirolimus
22 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers Active, not recruiting NCT00503035 Phase 2 Celecoxib
23 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Not yet recruiting NCT02961374 Phase 2 Erlotinib Hydrochloride
24 Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis. Not yet recruiting NCT03061591 Phase 2
25 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis Terminated NCT00033371 Phase 2 Celecoxib;eflornithine
26 Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Withdrawn NCT00248053 Phase 2 curcumin
27 Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Completed NCT02113202 Phase 1 Bevacizumab-IRDye800CW
28 Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP) Completed NCT00770991 Phase 1 Black raspberry (BRB) Slurry;Black Raspberry (BRB) Suppositories;Black Raspberry (BRB) Placebo Slurry
29 Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis Completed NCT00685568 Phase 1 celecoxib
30 A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers Completed NCT00813241 Phase 1 celecoxib reference formulation;celecoxib test formulation A1;celecoxib test formulation B2;celecoxib test formulation C1
31 Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action Completed NCT02060396 Phase 1 Acetylsalicylic acid
32 Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy Unknown status NCT00253812
33 Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway Unknown status NCT00498134 Triple therapy for H. pylori infection;Cox-2 inhibitor
34 Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch? Completed NCT01173250
35 A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome Completed NCT01286662
36 Dual Focus NBI and pCLE in FAP Related Duodenal Adenoma Completed NCT02162173
37 Genetic Analysis of Hereditary Prostate Cancer Completed NCT00001469
38 Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal Cancer Completed NCT03155542
39 Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study Completed NCT01764503
40 Oligogenic Determinism of Colorectal Cancer Completed NCT01057953
41 Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease Completed NCT01656746
42 Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer Completed NCT00675636
43 Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program Recruiting NCT02747862
44 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Recruiting NCT02656134
45 Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients Recruiting NCT01604564
46 French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperpl Recruiting NCT01987518
47 Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes Recruiting NCT02198092
48 18F-FES PET/CT in Imaging Patients With Desmoid Tumors Recruiting NCT02374931
49 Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal Adenomas Recruiting NCT02470416
50 Evaluation of Oesogastroduodenoscopy With Vision to 245 ° (Full Spectrum Endoscopy) to View the Main Disc and Accessory Recruiting NCT02859883

Search NIH Clinical Center for Adenomatous Polyposis Coli

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Adenomatous Polyposis Coli

Genetic tests related to Adenomatous Polyposis Coli:

id Genetic test Affiliating Genes
1 Familial Adenomatous Polyposis 1 29
2 Gardner Syndrome 29 24 APC
3 Brain Tumor-Polyposis Syndrome 2 29

Anatomical Context for Adenomatous Polyposis Coli

MalaCards organs/tissues related to Adenomatous Polyposis Coli:

39
Colon, Skin, Thyroid, Brain, Liver, Bone, Adrenal Gland

Publications for Adenomatous Polyposis Coli

Articles related to Adenomatous Polyposis Coli:

(show top 50) (show all 308)
id Title Authors Year
1
Adenomatous polyposis coli nucleates actin assembly to drive cell migration and microtubule-induced focal adhesion turnover. ( 28663347 )
2017
2
Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. ( 28490611 )
2017
3
Origin of Somatic Mutations in I^-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans. ( 28578586 )
2017
4
A metabolic switch controls intestinal differentiation downstream of Adenomatous polyposis coli (APC). ( 28397687 )
2017
5
Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. ( 28497891 )
2017
6
Extracellular inhibitors can attenuate tumorigenic Wnt pathway activity in adenomatous polyposis coli mutants: Predictions of a validated mathematical model. ( 28708837 )
2017
7
A novel mutation of adenomatous polyposis coli (APC) gene results in the formation of supernumerary teeth. ( 28782241 )
2017
8
Insulin signaling regulates a functional interaction between Adenomatous Polyposis Coli (APC) and cytoplasmic dynein. ( 28057765 )
2017
9
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli. ( 27334689 )
2016
10
Cribriform morular variant of papillary thyroid carcinoma: Cytomorphology, differential diagnosis and diagnostic implications in patients with adenomatous polyposis coli. ( 28028343 )
2016
11
Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. ( 28203651 )
2016
12
Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. ( 27798265 )
2016
13
Adenomatous polyposis coli (APC) regulates miR17-92 cluster through I^-catenin pathway in colorectal cancer. ( 26804172 )
2016
14
Adenomatous polyposis coli regulates radial axonal sorting and myelination in the PNS. ( 27226321 )
2016
15
Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. ( 26970738 )
2016
16
Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells. ( 26609171 )
2016
17
Deep vein thrombosis in a patient of adenomatous polyposis coli treated successfully with aspirin: A case report. ( 27386068 )
2016
18
Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. ( 26760960 )
2016
19
Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. ( 27028212 )
2016
20
Tumour Suppressor Adenomatous Polyposis Coli (APC) localisation is regulated by both Kinesin-1 and Kinesin-2. ( 27272132 )
2016
21
A novel pathogenic large germline deletion in adenomatous polyposis coli gene in a Chinese family with familial adenomatous polyposis. ( 27391059 )
2016
22
Characterization of Adenomatous Polyposis Coli Protein Dynamics and Localization at the Centrosome. ( 27144584 )
2016
23
miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. ( 27595705 )
2016
24
Association of CD24 and the adenomatous polyposis coli gene polymorphisms with oral lichen planus. ( 26187149 )
2015
25
Adenomatous polyposis coli (APC)-induced apoptosis of HT29 colorectal cancer cells depends on mitochondrial oxidative metabolism. ( 26004395 )
2015
26
A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. ( 26311738 )
2015
27
Tissue-Specific Effects of Reduced I^-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium. ( 26528816 )
2015
28
High-resolution Melting Analysis for Gene Scanning of Adenomatous Polyposis Coli (APC) Gene With Oral Squamous Cell Carcinoma Samples. ( 26447891 )
2015
29
MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression. ( 26028359 )
2015
30
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice. ( 26139199 )
2015
31
Expression and mutation pattern of I^-catenin and adenomatous polyposis coli in colorectal cancer patients. ( 25660336 )
2015
32
Mesenchymal adenomatous polyposis coli plays critical and diverse roles in regulating lung development. ( 26092405 )
2015
33
Adenomatous Polyposis Coli Mutation Leads to Myopia Development in Mice. ( 26495845 )
2015
34
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. ( 26334567 )
2015
35
Adenomatous Polyposis Coli Protein Deletion in Efferent Olivocochlear Neurons Perturbs Afferent Synaptic Maturation and Reduces the Dynamic Range of Hearing. ( 26085645 )
2015
36
Adenomatous polyposis coli mutants dominantly activate Hsf1-dependent cell stress pathways through inhibition of microtubule dynamics. ( 26320184 )
2015
37
Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)--a critical issue. ( 25586093 )
2015
38
Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations. ( 24664542 )
2014
39
The effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (I^-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin). ( 24390805 )
2014
40
Adenomatous polyposis coli gene large deletions in Iranian patients with familial adenomatous polyposis. ( 25494137 )
2014
41
N-terminal truncation mutations of adenomatous polyposis coli are associated with primary cilia defects. ( 25150829 )
2014
42
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. ( 25460919 )
2014
43
Low-grade neuroendocrine tumors arising in intestinal adenomas: evidence for alterations in the adenomatous polyposis coli/I^-catenin pathway. ( 25149552 )
2014
44
different Roles for the axin interactions with the SAMP versus the second twenty amino acid repeat of adenomatous polyposis coli. ( 24722208 )
2014
45
Early postoperative complications after stapled vs handsewn restorative proctocolectomy with ileal pouch-anal anastomosis in 148 patients with familial adenomatous polyposis coli: a matched-pair analysis. ( 23941307 )
2014
46
Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKKI^. ( 24613833 )
2014
47
Minimal access laparoscopic surgery for treatment of ulcerative colitis and familial adenomatous polyposis coli in children and adolescents. ( 25247476 )
2014
48
Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-I^-catenin signalling. ( 24251807 )
2014
49
HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction. ( 23277359 )
2013
50
Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the Adenomatous polyposis coli gene. ( 24005794 )
2013

Variations for Adenomatous Polyposis Coli

UniProtKB/Swiss-Prot genetic disease variations for Adenomatous Polyposis Coli:

71 (show all 11)
id Symbol AA change Variation ID SNP ID
1 APC p.Ser171Ile VAR_005032
2 APC p.Arg414Cys VAR_005033 rs137854567
3 APC p.Ser784Thr VAR_005034
4 APC p.Glu911Gly VAR_005038
5 APC p.Pro1176Leu VAR_005044
6 APC p.Thr1313Ala VAR_005051 rs863225349
7 APC p.Arg1348Trp VAR_005053
8 APC p.Ser2621Cys VAR_005056 rs72541816
9 APC p.Leu2839Phe VAR_005057 rs876658156
10 APC p.Ser722Gly VAR_009614
11 APC p.Ala1184Pro VAR_009616

ClinVar genetic disease variations for Adenomatous Polyposis Coli:

6 (show top 50) (show all 286)
id Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.730_731delAG (p.Arg244Valfs) deletion Pathogenic rs387906228 GRCh37 Chromosome 5, 112136976: 112136977
2 APC NM_000038.5(APC): c.1369delT (p.Ser457Hisfs) deletion Pathogenic rs387906229 GRCh37 Chromosome 5, 112157649: 112157649
3 APC NM_000038.5(APC): c.1500T> G (p.Tyr500Ter) single nucleotide variant Pathogenic rs387906230 GRCh37 Chromosome 5, 112162896: 112162896
4 APC NM_000038.5(APC): c.904C> T (p.Arg302Ter) single nucleotide variant Pathogenic rs137854568 GRCh37 Chromosome 5, 112151261: 112151261
5 APC NM_000038.5(APC): c.839C> G (p.Ser280Ter) single nucleotide variant Pathogenic rs137854569 GRCh37 Chromosome 5, 112151196: 112151196
6 APC NM_000038.5(APC): c.2138C> G (p.Ser713Ter) single nucleotide variant Pathogenic rs137854570 GRCh37 Chromosome 5, 112173429: 112173429
7 APC NM_000038.5(APC): c.4012C> T (p.Gln1338Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913327 GRCh37 Chromosome 5, 112175303: 112175303
8 APC NM_000038.5(APC): c.509_512delATAG (p.Asp170Valfs) deletion Pathogenic rs387906231 GRCh37 Chromosome 5, 112111412: 112111415
9 APC NM_000038.5(APC): c.1069dupA (p.Ile357Asnfs) duplication Pathogenic rs387906232 GRCh37 Chromosome 5, 112154798: 112154798
10 APC NM_000038.5(APC): c.1621C> T (p.Gln541Ter) single nucleotide variant Pathogenic rs137854572 GRCh37 Chromosome 5, 112163698: 112163698
11 APC NM_000038.5(APC): c.1660C> T (p.Arg554Ter) single nucleotide variant Pathogenic rs137854573 GRCh37 Chromosome 5, 112164586: 112164586
12 APC NM_000038.5(APC): c.1690C> T (p.Arg564Ter) single nucleotide variant Pathogenic rs137854574 GRCh37 Chromosome 5, 112164616: 112164616
13 APC NM_000038.5(APC): c.1885_1886insA (p.Leu629Tyrfs) insertion Pathogenic rs387906233 GRCh37 Chromosome 5, 112170789: 112170790
14 APC NM_000038.5(APC): c.2805C> A (p.Tyr935Ter) single nucleotide variant Pathogenic rs137854575 GRCh37 Chromosome 5, 112174096: 112174096
15 APC NM_000038.5(APC): c.4393_4394delAG (p.Ser1465Trpfs) deletion Pathogenic rs387906234 GRCh37 Chromosome 5, 112175684: 112175685
16 APC NM_000038.5(APC): c.4391_4394delAGAG (p.Glu1464Valfs) deletion Pathogenic rs387906235 GRCh37 Chromosome 5, 112175682: 112175685
17 APC NM_000038.5(APC): c.470G> A (p.Trp157Ter) single nucleotide variant Pathogenic rs137854576 GRCh37 Chromosome 5, 112111373: 112111373
18 APC NM_000038.5(APC): c.643C> T (p.Gln215Ter) single nucleotide variant Pathogenic rs137854577 GRCh37 Chromosome 5, 112116598: 112116598
19 APC NC_000005.10: g.112836913_112908314del71402 deletion Pathogenic GRCh37 Chromosome 5, 112172610: 112244011
20 APC NM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs) deletion Pathogenic rs121913224 GRCh37 Chromosome 5, 112175218: 112175222
21 APC NM_000038.5(APC): c.5942delA (p.Asn1981Ilefs) deletion Pathogenic rs397509433 GRCh37 Chromosome 5, 112177233: 112177233
22 APC NM_000038.5(APC): c.5582_5585delCTTT (p.Ser1861Terfs) deletion Pathogenic rs587776520 GRCh38 Chromosome 5, 112841176: 112841179
23 APC NM_000038.5(APC): c.3920T> A (p.Ile1307Lys) single nucleotide variant risk factor rs1801155 GRCh37 Chromosome 5, 112175211: 112175211
24 APC NM_000038.5(APC): c.4611_4612delAG (p.Glu1538Ilefs) deletion Pathogenic rs387906236 GRCh37 Chromosome 5, 112175902: 112175903
25 APC NM_000038.5(APC): c.1495C> T (p.Arg499Ter) single nucleotide variant Pathogenic rs137854580 GRCh37 Chromosome 5, 112162891: 112162891
26 APC APC, TYR486TER single nucleotide variant Pathogenic
27 APC NM_000038.5(APC): c.1311_1312+1delAAG deletion Pathogenic rs397514030 GRCh37 Chromosome 5, 112155040: 112155042
28 APC NM_000038.5(APC): c.1192_1193delAA (p.Lys398Glufs) deletion Pathogenic rs387906238 GRCh37 Chromosome 5, 112154921: 112154922
29 APC NM_000038.5(APC): c.937_938delGA (p.Glu313Asnfs) deletion Pathogenic rs387906239 GRCh37 Chromosome 5, 112154666: 112154667
30 APC NM_000038.5(APC): c.2093T> A (p.Leu698Ter) single nucleotide variant Pathogenic rs137854582 GRCh37 Chromosome 5, 112173384: 112173384
31 APC APC deletion deletion Pathogenic GRCh38 Chromosome 5, 112707504: 112846240
32 APC NM_000038.5(APC): c.423-1G> A single nucleotide variant Pathogenic rs397514031 GRCh37 Chromosome 5, 112111325: 112111325
33 APC NM_000038.5(APC): c.1059_1060insAAGGATGATAT (p.Pro354Lysfs) insertion Pathogenic GRCh38 Chromosome 5, 112819091: 112819092
34 APC NM_000038.5(APC): c.622C> T (p.Gln208Ter) single nucleotide variant Pathogenic rs137854583 GRCh37 Chromosome 5, 112116577: 112116577
35 APC NG_008481.4: g.(?_150033)_(158719_?)del deletion Pathogenic GRCh38 Chromosome 5, 112837553: 112846239
36 APC APC, 5-BP DEL, NT3221 deletion Pathogenic
37 APC NM_000038.5(APC): c.1917dupA (p.Arg640Thrfs) duplication Likely pathogenic rs397515732 GRCh37 Chromosome 5, 112170821: 112170821
38 APC NM_000038.5(APC): c.3162delC (p.His1054Glnfs) deletion Pathogenic rs397515733 GRCh37 Chromosome 5, 112174453: 112174453
39 APC NM_000038.5(APC): c.694C> T (p.Arg232Ter) single nucleotide variant Pathogenic rs397515734 GRCh37 Chromosome 5, 112128191: 112128191
40 APC NM_000038.5(APC): c.896_897delCT (p.Ser299Cysfs) deletion Pathogenic rs397515735 GRCh37 Chromosome 5, 112151253: 112151254
41 APC NM_000038.5(APC): c.190G> T (p.Gly64Ter) single nucleotide variant Pathogenic rs79323615 GRCh37 Chromosome 5, 112102077: 112102077
42 APC NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs) deletion Pathogenic rs587779352 GRCh37 Chromosome 5, 112174474: 112174478
43 APC NM_000038.5(APC): c.3202_3205delTCAA (p.Ser1068Glyfs) deletion Pathogenic rs587779353 GRCh37 Chromosome 5, 112174493: 112174496
44 APC NM_000038.5(APC): c.1659G> A (p.Trp553Ter) single nucleotide variant Pathogenic rs398123116 GRCh37 Chromosome 5, 112164585: 112164585
45 APC NM_000038.5(APC): c.2365C> T (p.Gln789Ter) single nucleotide variant Pathogenic rs398123117 GRCh37 Chromosome 5, 112173656: 112173656
46 APC NM_000038.5(APC): c.2547_2550delTAGA (p.Asp849Glufs) deletion Pathogenic rs398123118 GRCh37 Chromosome 5, 112173838: 112173841
47 APC NM_000038.5(APC): c.2731G> T (p.Glu911Ter) single nucleotide variant Pathogenic rs398123119 GRCh37 Chromosome 5, 112174022: 112174022
48 APC NM_000038.5(APC): c.2805delC (p.Tyr935Terfs) deletion Pathogenic rs398123120 GRCh37 Chromosome 5, 112174096: 112174096
49 APC NM_000038.5(APC): c.3982C> T (p.Gln1328Ter) single nucleotide variant Pathogenic rs398123121 GRCh37 Chromosome 5, 112175273: 112175273
50 APC NM_000038.5(APC): c.4473dupT (p.Ala1492Cysfs) duplication Pathogenic rs398123122 GRCh37 Chromosome 5, 112175764: 112175764

Expression for Adenomatous Polyposis Coli

Search GEO for disease gene expression data for Adenomatous Polyposis Coli.

Pathways for Adenomatous Polyposis Coli

Pathways related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 AMER1 APC AXIN1 AXIN2 CCND1 CDH1
2
Show member pathways
13.63 AMER1 APC AXIN1 CDH1 CTNNB1 GSK3B
3
Show member pathways
12.91 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
4 12.71 APC APC2 AXIN1 AXIN2 CCND1 CTNNB1
5
Show member pathways
12.54 CCND1 CTNNB1 GSK3B MYC
6
Show member pathways
12.54 APC APC2 AXIN1 AXIN2 CCND1 CDH1
7
Show member pathways
12.54 APC APC2 AXIN1 AXIN2 CCND1 CTNNB1
8
Show member pathways
12.52 APC AXIN1 AXIN2 CCND1 CTNNB1
9 12.48 APC APC2 CCND1 CTNNB1 GSK3B MYC
10 12.47 APC APC2 CCND1 MYC
11 12.47 APC AXIN1 CCND1 CDH1 CTNNB1 GSK3B
12
Show member pathways
12.46 APC AXIN1 AXIN2 GSK3B
13
Show member pathways
12.43 APC AXIN1 CTNNB1 GSK3B
14
Show member pathways
12.42 APC APC2 AXIN1 AXIN2 CTNNB1 GSK3B
15 12.41 APC APC2 AXIN1 AXIN2 CCND1 CDH1
16 12.39 APC CCND1 CDH1 GSK3B MYC
17
Show member pathways
12.36 AXIN1 AXIN2 CTNNB1 GSK3B
18
Show member pathways
12.31 CCND1 CTNNB1 GSK3B MYC
19 12.3 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
20
Show member pathways
12.26 APC CDH1 CTNNB1 GSK3B
21
Show member pathways
12.25 APC AXIN1 AXIN2 CTNNB1 GSK3B
22 12.16 APC AXIN1 CDH1 CTNNB1 GSK3B
23 12.15 CCND1 CDH1 CTNNB1 MYC
24 12.13 APC AXIN2 CCND1 CDH1 CTNNB1 GSK3B
25 12.09 APC AXIN1 CDH1 CTNNB1 GSK3B
26
Show member pathways
12.05 CCND1 CTNNB1 GSK3B
27 12.05 APC AXIN1 CCND1 CTNNB1 GSK3B MYC
28 12.04 APC CTNNB1 GSK3B
29 12.02 APC AXIN1 CCND1 CTNNB1 GSK3B MYC
30 12.01 AXIN1 CCND1 MYC
31 12.01 APC APC2 AXIN1 AXIN2 CTNNB1 GSK3B
32 12 CCND1 CTNNB1 GSK3B MYC
33 11.96 APC AXIN1 CTNNB1 GSK3B
34 11.96 AXIN1 AXIN2 CDH1 CTNNB1 GSK3B MYC
35
Show member pathways
11.94 APC CDH1 CTNNB1
36 11.83 CCND1 CTNNB1 GSK3B
37 11.83 APC AXIN2 CCND1 CDH1 CTNNB1 MYC
38 11.79 APC AXIN1 CTNNB1 GSK3B MYC
39 11.72 CCND1 CDH1 MYC
40 11.58 APC CCND1 GSK3B
41
Show member pathways
11.57 CCND1 GSK3B MYC
42
Show member pathways
11.49 CCND1 GSK3B MYC
43 11.46 APC APC2 AXIN1 AXIN2 CCND1 CDH1
44 11.4 CDH1 CTNNB1 MAPRE1 MAPRE2 MAPRE3
45 11.4 APC AXIN1 CCND1 CTNNB1 GSK3B MYC
46 11.35 CCND1 CDH1 CTNNB1
47 11.35 AXIN1 CTNNB1 MAPRE1
48 11.3 APC AXIN1 CTNNB1
49 11.22 APC AXIN1 AXIN2 CCND1 CTNNB1 GSK3B
50 11.18 APC AXIN2 CCND1 CTNNB1 GSK3B

GO Terms for Adenomatous Polyposis Coli

Cellular components related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.92 APC APC2 AXIN1 CDH1 CTNNB1
2 centrosome GO:0005813 9.85 APC AXIN2 CTNNB1 GSK3B MAPRE1
3 microtubule GO:0005874 9.77 APC APC2 MAPRE1 MAPRE2 MAPRE3
4 lamellipodium GO:0030027 9.74 APC CDH1 CTNNB1
5 bicellular tight junction GO:0005923 9.73 APC CCND1 CTNNB1
6 microtubule cytoskeleton GO:0015630 9.73 APC2 MAPRE1 MAPRE2 MAPRE3
7 cell-cell adherens junction GO:0005913 9.65 APC CDH1 CTNNB1
8 lateral plasma membrane GO:0016328 9.56 APC AXIN1 CDH1 CTNNB1
9 apical junction complex GO:0043296 9.55 CDH1 CTNNB1
10 cell projection membrane GO:0031253 9.51 CTNNB1 MAPRE1
11 microtubule plus-end GO:0035371 9.5 MAPRE1 MAPRE2 MAPRE3
12 flotillin complex GO:0016600 9.49 CDH1 CTNNB1
13 Wnt signalosome GO:1990909 9.33 APC CTNNB1 GSK3B
14 catenin complex GO:0016342 9.26 APC APC2 CDH1 CTNNB1
15 beta-catenin destruction complex GO:0030877 9.02 APC AXIN1 AXIN2 CTNNB1 GSK3B
16 cytoplasm GO:0005737 10.18 AMER1 APC APC2 AXIN1 AXIN2 CCND1
17 cytoskeleton GO:0005856 10.01 APC APC2 CTNNB1 MAPRE1 MAPRE2 MAPRE3

Biological processes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.92 AXIN1 CDH1 CTNNB1 MAPRE3 MYC
2 cell division GO:0051301 9.9 CCND1 MAPRE1 MAPRE2 MAPRE3
3 cell proliferation GO:0008283 9.89 AXIN2 CTNNB1 MAPRE1 MAPRE2
4 response to drug GO:0042493 9.88 CCND1 CDH1 CTNNB1 MYC
5 protein deubiquitination GO:0016579 9.84 APC AXIN1 AXIN2 MYC
6 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 9.8 AMER1 APC AXIN1 CTNNB1 GSK3B
7 negative regulation of canonical Wnt signaling pathway GO:0090090 9.8 AMER1 APC APC2 AXIN1 AXIN2 GSK3B
8 positive regulation of protein phosphorylation GO:0001934 9.79 AXIN1 AXIN2 CCND1
9 positive regulation of canonical Wnt signaling pathway GO:0090263 9.76 AMER1 AXIN1 AXIN2
10 canonical Wnt signaling pathway GO:0060070 9.73 APC AXIN1 CCND1 CTNNB1 GSK3B MYC
11 positive regulation of protein catabolic process GO:0045732 9.69 APC AXIN1 GSK3B
12 negative regulation of Wnt signaling pathway GO:0030178 9.67 APC APC2 AXIN1 CCND1
13 beta-catenin-TCF complex assembly GO:1904837 9.65 AXIN2 CTNNB1 MYC
14 positive regulation of mesenchymal cell proliferation GO:0002053 9.62 CTNNB1 MYC
15 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.61 CCND1 MAPRE3
16 entry of bacterium into host cell GO:0035635 9.57 CDH1 CTNNB1
17 negative regulation of catenin import into nucleus GO:0035414 9.56 APC2 AXIN2
18 regulation of microtubule-based process GO:0032886 9.55 APC GSK3B
19 cellular response to indole-3-methanol GO:0071681 9.49 CDH1 CTNNB1
20 regulation of centromeric sister chromatid cohesion GO:0070602 9.46 AXIN2 CTNNB1
21 beta-catenin destruction complex assembly GO:1904885 9.46 AMER1 APC AXIN1 GSK3B
22 positive regulation of microtubule plus-end binding GO:1903033 9.43 MAPRE1 MAPRE3
23 beta-catenin destruction complex disassembly GO:1904886 9.35 AMER1 APC AXIN1 CTNNB1 GSK3B
24 Wnt signaling pathway GO:0016055 9.23 AMER1 APC APC2 AXIN1 AXIN2 CCND1

Molecular functions related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.89 APC AXIN1 MAPRE1 MAPRE2 MAPRE3
2 enzyme binding GO:0019899 9.78 AXIN1 AXIN2 CCND1 CTNNB1
3 ubiquitin protein ligase binding GO:0031625 9.73 APC AXIN1 AXIN2 GSK3B
4 cadherin binding GO:0045296 9.71 APC CDH1 CTNNB1 MAPRE1
5 protein kinase binding GO:0019901 9.65 APC AXIN1 CCND1 CTNNB1 GSK3B
6 microtubule binding GO:0008017 9.55 APC APC2 MAPRE1 MAPRE2 MAPRE3
7 microtubule plus-end binding GO:0051010 9.46 APC MAPRE1
8 gamma-catenin binding GO:0045295 9.37 APC CDH1
9 beta-catenin binding GO:0008013 9.17 AMER1 APC APC2 AXIN1 AXIN2 CDH1
10 I-SMAD binding GO:0070411 9.13 AXIN1 AXIN2 CTNNB1
11 protein binding GO:0005515 10.13 AMER1 APC APC2 AXIN1 AXIN2 CCND1

Sources for Adenomatous Polyposis Coli

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....